CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA

RegulatoryapprovedCeQurPositive

AI Analysis

Summary

CeQur announced two FDA clearances for extended 7-day wear and 1-unit dosing capabilities for its mealtime insulin delivery system, with new clinical evidence to be presented at the American Diabetes Association conference.

Outcome Details

Two FDA clearances for extended 7-day wear and 1-unit dosing

Importance:7/10

Sentiment:

0.80

FDA clearanceinsulin deliverydiabetesmedical deviceADA conference

Read the original article

Published by PR Newswire Clinical Trials on June 4, 2026 10:00 AM

Read Original